×

Pharmaceutical formulations comprising an insulin derivative

  • US 9,034,818 B2
  • Filed: 06/12/2008
  • Issued: 05/19/2015
  • Est. Priority Date: 06/13/2007
  • Status: Active Grant
First Claim
Patent Images

1. A soluble pharmaceutical formulation comprising dodecamers of insulin derivative wherein the formulation further comprisesa) more than 4 zinc atoms per 6 molecules of the insulin derivative,b) citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers,wherein the insulin derivative is a parent insulin with an ε

  • -amino group of a Lys residue present in the B chain of the parent insulin acylated and wherein the insulin derivative can be modified from the parent insulin by up to one further modification selected from the group consisting of the addition of one amino acid to the parent insulin, deletion of one amino acid from the parent insulin or the exchange of one amino acid from the parent insulin, wherein at least about 76% of the insulin derivative molecules are present as dodecamers when measured by SEC with phenol after storage at 37°

    C. for 4 weeks.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×